{"id":69172,"date":"2026-07-03T08:07:57","date_gmt":"2026-07-03T06:07:57","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/il-33-scripts-cancer-immunity-marek-wagner\/"},"modified":"2026-07-03T08:07:57","modified_gmt":"2026-07-03T06:07:57","slug":"il-33-scripts-cancer-immunity-marek-wagner","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/il-33-scripts-cancer-immunity-marek-wagner\/","title":{"rendered":"IL-33 scripts cancer immunity. Marek Wagner"},"content":{"rendered":"<div>\n<p><b>Trends Immunol<\/b>. 2026 Jul 2:S1471-4906(26)00162-6. doi: 10.1016\/j.it.2026.06.006. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Interleukin-33 (IL-33) is classically viewed as an alarmin, but in cancer, it may do more than merely initiate immunity. I propose that IL-33 scripts the trajectory of immunity through interconnected regulatory layers that influence how host responses are organized and ultimately resolved into either productive antitumor immunity or suppressive, repair-like states.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42392913\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=100966032&amp;ff=20260703020757&amp;v=2.20.0\">42392913<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.it.2026.06.006\">10.1016\/j.it.2026.06.006<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Trends Immunol. 2026 Jul 2:S1471-4906(26)00162-6. doi: 10.1016\/j.it.2026.06.006. Online ahead of print. ABSTRACT Interleukin-33 (IL-33) is classically viewed as an alarmin, but in cancer, it may do more than merely initiate immunity. I propose that IL-33 scripts the trajectory of immunity through interconnected regulatory layers that influence how host responses are organized and ultimately resolved into &#8230; <a title=\"IL-33 scripts cancer immunity. Marek Wagner\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/07\/03\/il-33-scripts-cancer-immunity-marek-wagner\/\" aria-label=\"Read more about IL-33 scripts cancer immunity. Marek Wagner\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,68],"tags":[],"class_list":["post-69172","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-trends-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/69172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=69172"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/69172\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=69172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=69172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=69172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}